The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy Virtual 2020 | Saad Usmani: BELLINI, CANDOR, ICARIA-MM and CAR-T
Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the optimal choice of therapy beyond first relapse in multiple myeloma. The BELLINI, CANDOR and ICARIA-MM trials (NCT02755597, NCT03158688, NCT02990338) are discussed, as are CAR-T cell approaches to therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
